Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NUBEQA vs WINLEVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.
WINLEVI (clascoterone) is a topical androgen receptor inhibitor. It binds to the androgen receptor, preventing androgen-mediated signaling in sebocytes and inflammatory cells, thereby reducing sebum production and inflammation.
Treatment of patients with non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of patients with metastatic hormone-sensitive prostate cancer (m HSPC) in combination with docetaxel
FDA-approved for the topical treatment of acne vulgaris in patients aged 12 years and older.
600 mg orally twice daily with food.
WINLEVI (clascoterone) topical cream 1%: Apply a thin layer to the affected skin areas twice daily, in the morning and evening.
Terminal elimination half-life is approximately 20 hours; supports once-daily dosing.
Terminal elimination half-life is approximately 7.3 hours following topical application of clascoterone 1% cream. This supports twice-daily dosing for maintaining therapeutic drug levels.
Primarily metabolized by CYP3A4 and also by CYP2C8 and UGT1A1 to a lesser extent.
Clascoterone is metabolized primarily by CYP3A4 and CYP2C8 to its major metabolite, cortexolone. It undergoes extensive first-pass metabolism if absorbed systemically.
Primarily excreted as unchanged drug via feces (approximately 63.7%) and urine (approximately 23.8%); minimal biliary excretion.
Primarily fecal (approximately 84% of the dose) and renal (approximately 2.5% of the dose) following intravenous administration. Unchanged drug accounts for less than 1% in urine and feces.
Approximately 97% bound to plasma proteins (primarily albumin).
Approximately 72% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
Apparent volume of distribution is approximately 98 L (1.2 L/kg for a 80 kg patient), indicating extensive tissue distribution.
Following intravenous administration, volume of distribution is approximately 1.8 L/kg, indicating extensive tissue distribution.
Absolute oral bioavailability is approximately 21% (fasted state); increased by 2.6-fold with a high-fat meal.
Systemic bioavailability is minimal after topical application of clascoterone 1% cream, with plasma concentrations typically below the limit of quantitation; the exact percentage is not determined, but systemic exposure is negligible (<1% of applied dose).
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
No dosage adjustment required for renal impairment, as systemic absorption is minimal.
Child-Pugh A: No adjustment. Child-Pugh B: Not recommended. Child-Pugh C: Contraindicated.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Safety and efficacy not established; no recommended dose.
Approved for patients aged 12 years and older. Same dosing as adults: apply a thin layer of 1% cream twice daily to affected areas. Safety and efficacy in children under 12 years have not been established.
No dose adjustment required based on age alone; monitor for adverse effects.
No specific dosage adjustment needed. However, elderly patients may have more sensitive skin; monitor for local irritation. Systemic exposure is minimal.
None.
None.
Ischemic cardiovascular events,Hypertension,Fractures,Seizures,Posterior reversible encephalopathy syndrome (PRES),Hypersensitivity reactions,Fetal toxicity
Local skin reactions including erythema, pruritus, and scaling may occur. Avoid contact with eyes, mouth, and mucous membranes. Not for oral, ophthalmic, or intravaginal use. Discontinue if signs of systemic toxicity or hypersensitivity develop. Use in pregnancy only if clearly needed; no adequate and well-controlled studies exist.
Pregnancy,Severe hepatic impairment (Child-Pugh C)
Hypersensitivity to clascoterone or any component of the formulation.
Take with food to increase absorption; food with moderate-to-high fat content enhances bioavailability. Avoid grapefruit juice or products containing grapefruit as they may inhibit P-gp and increase darolutamide levels.
No specific food interactions are known. No dietary restrictions are required.
NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse developmental effects including embryotoxicity and malformations in rats at exposures below human clinical exposure. No adequate human data exist. It should not be used in pregnant women or those planning to become pregnant. If exposure occurs during pregnancy, the patient should be apprised of the potential hazard to the fetus.
WINLEVI (clascoterone) is a topical androgen receptor inhibitor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm was observed following topical administration of clascoterone during organogenesis at doses up to 2.5 mg/kg/day in rats (systemic exposure ~27 times the MRHD based on AUC) and 50 mg/kg/day in rabbits (systemic exposure 4 times the MRHD). However, because systemic absorption is minimal, the risk is considered low. Per FDA labeling, use during pregnancy only if clearly needed. No known fetal risks by trimester; avoid use on large areas of broken skin.
It is unknown whether darolutamide or its metabolites are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment with NUBEQA and for at least 1 week after the final dose. The milk-to-plasma ratio (M/P ratio) is not available.
It is not known whether clascoterone is excreted in human milk after topical application. Systemically absorbed clascoterone is minimal; however, it is lipophilic and may partition into breast milk. No M/P ratio is available. Due to potential for serious adverse reactions in nursing infants, advise patients to avoid application to the breast area and to discontinue nursing or drug, taking into account importance of drug to mother.
No dosing adjustment recommendations are available for use during pregnancy because NUBEQA is contraindicated in pregnant women. There are no clinical data regarding the pharmacokinetic changes in pregnancy, and no studies have evaluated the need for dose adjustment in this population. Therefore, no specific dose adjustments for pregnancy are provided.
No dose adjustment required in pregnancy due to minimal systemic absorption and lack of pharmacokinetic changes reported. Use with caution for acne treatment during pregnancy; weigh benefit vs risk. Apply thin layer once daily; avoid use on large areas of damaged skin.
NUBEQA (darolutamide) is a non-steroidal androgen receptor inhibitor with low blood-brain barrier penetration, reducing CNS side effects like falls and fractures. Monitor for cardiovascular events and hypertension; dose adjustment required in severe renal impairment (e GFR 15-29 m L/min) or moderate hepatic impairment (Child-Pugh B). Administer with food to enhance absorption. No dose adjustment for mild renal or hepatic impairment.
WINLEVI (clascoterone) is a topical androgen receptor inhibitor approved for acne vulgaris. Avoid use on broken or eczematous skin. Monitor for signs of hyperkalemia in patients with renal impairment or those taking medications affecting potassium. Application should be limited to 1 gram per day (approximately 4 pump actuations) to minimize systemic absorption. Can be used in conjunction with other topical acne therapies but may require adjustment of irritation potential.
Take NUBEQA with food at the same time each day.,Swallow tablets whole; do not crush, chew, or split.,Do not take with strong P-glycoprotein (P-gp) inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole).,Report unusual bleeding, bruising, or signs of bleeding (e.g., blood in urine or stool).,Use effective contraception during treatment and for 1 week after last dose if partner could become pregnant.,Inform your doctor if you have severe kidney or moderate liver problems.
Apply a thin layer to clean, dry skin once daily in the morning or evening as directed.,Do not apply to broken, cut, or sunburned skin.,Avoid contact with eyes, lips, and mucous membranes; if contact occurs, rinse with water.,Use sunscreen and protective clothing as WINLEVI may increase sun sensitivity.,Inform your doctor if you have kidney problems or are taking potassium-sparing diuretics or ACE inhibitors due to risk of hyperkalemia.,Do not use more than the prescribed amount; overdose can lead to systemic androgen blockade.,Store at room temperature (20°C-25°C) and keep out of reach of children.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NUBEQA vs WINLEVI, answered by our medical review team.
NUBEQA is a Androgen Receptor Inhibitor that works by Androgen receptor inhibitor; binds to the androgen receptor and inhibits nuclear translocation, DNA binding, and recruitment of coactivators, thereby reducing prostate cancer cell proliferation.. WINLEVI is a Topical Androgen Receptor Inhibitor that works by WINLEVI (clascoterone) is a topical androgen receptor inhibitor. It binds to the androgen receptor, preventing androgen-mediated signaling in sebocytes and inflammatory cells, thereby reducing sebum production and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NUBEQA and WINLEVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NUBEQA is: 600 mg orally twice daily with food.. The standard adult dose of WINLEVI is: WINLEVI (clascoterone) topical cream 1%: Apply a thin layer to the affected skin areas twice daily, in the morning and evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NUBEQA and WINLEVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NUBEQA is classified as Category C. NUBEQA (darolutamide) is contraindicated in pregnancy. Based on its mechanism of action (androgen receptor inhibition), it can cause fetal harm. Animal studies have shown adverse d. WINLEVI is classified as Category C. WINLEVI (clascoterone) is a topical androgen receptor inhibitor. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal har. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.